DOCSLIB.ORG

Pathhunter® Express Receptor Tyrosine Kinase Functional Assay

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathhunter® Express Receptor Tyrosine Kinase Functional Assay Contact Information 70-270 DRx_UM_PHeX_RTK_0514V6 DiscoveRx Corporation (World Wide Headquarters) 42501 Albrae Street ® Fremont, CA 94538 PathHunter eXpress Receptor United States Tyrosine Kinase Functional t | 510.979.1415 f | 510.979.1650 Assay Kit toll-free | 866.448.4864 DiscoveRx Corporation Ltd. (Europe Headquarters) Faraday Wharf, Holt Street User Manual Birmingham Science Park Aston Birmingham, B7 4BB United Kingdom t | +44.121.260.6142 f | +44.121.260.6143 KINOMEscan® A division of DiscoveRx 11180 Roselle Street, Suite D San Diego, CA 92121 United States t | 800.644.5687 f | 858.630.4600 BioSeek® A division of DiscoveRx 310 Utah Avenue, Suite 100 South San Francisco, CA 94080 United States t | 1.650.416.7600 f | 1.650.416.7625 www.discoverx.com © 2014 DiscoveRx Corporation, Fremont, CA 94538. All rights reserved. Simple Solutions for Complex Biology CONTENTS Appendix Target Partner Cell Line eXpress Reference DiscoveRx Cell Plating LEGAL SECTION PAGE 3 Protein Product Product Code Agonist Part # Reagent Code DiscoveRx Part # INTENDED USE PAGE 4 Receptor Tyrosine Kinase Assays TECHNOLOGY PRINCIPLE PAGE 4 C-MET GrB2 93-0632C3 HGF 92-1140 93-0563R16A DDR1 SHC1 93-0578C3 93-0578E3CP16 Collagen Type II 92-1090 93-0563R16A STORAGE CONDITIONS PAGE 5 DDR2 PLCG1 93-0711C3 Collagen Type II 92-1090 93-0563R16A MATERIALS PROVIDED PAGE 5 EphB4 SHC1 93-0468C3 93-0468E3CP16 Ephrin B2 FC 92-1089 93-0563R16A MATERIALS NOT PROVIDED PAGE 6 ErbB1 PLCG1 93-0681C3 EGF 92-1113 93-0563R16A ErbB2/ GrB2 93-0535C3 93-0535E3CP16 Heregulin 92-1031 93-0563R16A MEDIA REQUIREMENTS PAGE 6 ErbB3 ErbB4 SHC1 93-0465C3 NRG1 92-1091 93-0563R16A ASSAY PROCEDURE - AGONIST DOSE RESPONSE PAGE 6 FGFR4 PLCG2 93-0467C3 93-0467C3CP16 FGF-Basic 92-1027 93-0563R16A QUICK START PROCEDURE - AGONIST DOSE RESPONSE PAGE 9 Flt3 P85 93-0506C3 FLT3-Ligand 92-1029 93-0563R16A ASSAY PROCEDURE - ANTAGONIST DOSE RESPONSE PAGE 10 IGFR1 SHC1 93-0505C1 93-0505E1CP17 IGF1 92-1030 93-0563R17A INSR PLCG1 93-0466C3 93-0466E3CP16 Insulin 92-1088 93-0563R16A QUICK-START PROCEDURE - ANTIBODY DOSE RESPONSE PAGE 12 PDGFRb PLCG1 93-0469C3 93-0493E3CP16 PDGFA-B 92-1028 93-0563R16A FREQUENTLY ASK QUESTIONS PAGE 13 TrkA SHC1 93-0462C3 93-0462E3CP16 b-NGF 92-1023 93-0563R16A PLATE MAPS PAGE 14 TrkA- SHC1 93-0529C3 93-0529E3CP16 b-NGF 92-1023 93-0563R16A P75 TrkB SHC1 93-0463C3 BDNF 92-1024 93-0563R16A TrkB- SHC1 93-0530C3 93-0530E3CP16 BDNF 92-1024 93-0563R16A P75 ATTENTION: TrkC SHC1 93-0464C3 93-0464E3CP16 NT3 92-1025 93-0563R16A Read the entire product insert prior to beginning the assay. Refer to TrkC- SHC1 93-0531C3 NT3 92-1025 93-0563R16A the data sheets for additional information on cell-line specific media P75 requirements. Cytosolic Tyrosine Kinase Assays PRLR- PLCG2 93-0686C3 Prolactin 92-1144 93-0563R0A For additional information or Technical Support, contact DiscoveRx or JAK1 visit www.discoverx.com. PRLR- PLCG2 93-0687C3 Prolactin 92-1144 93-0563R0A JAK2 2 15 A. Agonist Dose Response (96-well plate layout): LEGAL SECTION This product and/or its use is covered by one or more US and/or foreign patents, patents applications, and trade secrets that are either owned or licensed to DiscoveRx corporation. For some products/cell lines, certain third party gene- specific patents may be required to use the cell line. It is Purchaser’s responsibil- ity to determine if such patents or other intellectual property rights are required. DiscoveRx® and PathHunter® are registered trademarks of DiscoveRx Corporation. DiscoveRx name and logo are a trademark of DiscoveRx Corporation. GraphPad Prism is a registered trademark of GraphPad Software, Inc. © 2014 DiscoveRx Corporation. All rights reserved. All goods and services sold are subject to the terms and conditions of DiscoveRx Corporation. A copy of these terms and conditions is available on request. Contact your local DiscoveRx representative for the most current information. This illustration shows an 11-point dose curve with 2 data points each 4 compounds per plate for a total of 8 compounds per eXpress kit. For additional info or further questions regarding the rights conferred with purchase of the Materials, please contact: Licensing Department B. Antibody/Inhibitor Dose Response (96-well plate layout): DiscoveRx Corporation 42501 Albrae Street Fremont, CA 94538 t | 510.979.1415 x 104 e | [email protected] This illustration shows a 10-point dose curve with 2 data points each 4 compounds per plate for a total of 8 compounds per eXpress kit. 14 3 INTENDED USE FREQUENTLY ASKED QUESTIONS PathHunter® eXpress Receptor Tyrosine Kinase (RTK) Functional Assay kits provide Q: I did not see a signal with my control agonist. a robust, highly sensitive and easy-to-use, cell-based functional assay for monitor- A1: There may be differences in agonist purchased from different vendors. ing receptor tyrosine kinase activation, phosphorylation and recruitment of SH2 A2: Confirm that the control agonist used is the same ligand used in the dose containing domain. The eXpress kits contain everything needed for a complete RTK response shown in the provided cell-specific data sheet. experiment including cells, detection reagents, media and plates*. The pre- A3: Please check if appropriate compound diluent was used. validated, frozen eXpress cells have been manufactured for short term use and are provided in a ready-to-assay format that saves time and adds convenience. Assays Q: I did not see a response with my compound. have been designed for 96-well plate analyses. A1: The concentration of DMSO or Ethanol used for dilution is too high. Maintain concentration of the agonist/antagonist diluent at ≤ 1%. *Test compounds are not included and must be provided by the researcher. Please refer to A2: Confirm that the final ligand concentration is correct. Some ligands are DiscoveRx ligands of choice for these assays on Appendix 1. “sticky” and difficult to dissolve. A3: Confirm that the cell line responds to the control agonist. A4: Repeat the experiment using a new lot of control agonist. A5: Please check if appropriate compound diluent was used. TECHNOLOGY PRINCIPLE: PATHHUNTER RECEPTOR TYROSINE KI- NASE ASSAY Q: My cells arrived thawed. Can I use them? A: No. Call technical support for a replacement. Assay-Ready frozen cells are based on DiscoveRx’s PathHunter technology. Path- Hunter cell lines feature novel in vivo applications of Enzyme Fragment Comple- Q: How long is the prepared detection reagent good for? mentation (EFC) technology in which the β-galactosidase (β-gal) enzyme has been A: The working detection reagent solution must be used within 8 hours of mixing. split into two inactive fragments. In the PathHunter assay approach for receptor tyrosine kinases, a small 4 kDa complementing fragment of β-gal (i.e., the ProLink™ Q: What instruments can I use to read the plates? tag) has been fused recombinantly to the intracellular C-terminus of the receptor A: Any bench top luminometer will work with the PathHunter eXpress assays. tyrosine kinase of interest. The larger portion of β-gal, termed EA for ‘enzyme acceptor’, is fused to many different partner proteins containing phospho-tyrosine Q: How long is the signal stable for? binding domains (such as SHC1, SHC2, Grb2, PTPN6, PLCG1 or PLCG2), depending A: The signal is stable for 2-3 hours after addition of detection reagent. on the RTK target. Ligand-induced activation of the receptor causes either homo- or hetero-dimerization of the receptor which results in cross-phosphorylation Q: My cells are floating after the 24 hours incubation. (Figure 1). The SH2-EA fusion protein then specifically binds the phosphorylated A: The cells are not viable, contact technical support for a replacement. receptor resulting in complementation of the two fragments of β-gal and formation of a functional enzyme. β-gal activity is then quantitatively detected using the Q: I ran out the cell plating reagent, can I buy it separately. chemiluminescent substrate in the PathHunter Detection Kit. A: Yes, the reagents are available, please see page 15 for more details. Q: How do I generate a dose curve for my agonist compound? A: Prepare eleven serial 4-fold dilutions of the agonist compound in the desired vehicle of choice. Prepare agonist dilutions such that the concentration is 11X of the final screening concentration (10 µl agonist + 100 µl cells). Pipette all compound dilutions following the plate map on page 14. Q: What Protocol can I use for Antibody studies? A: You can use the inhibitor protocol for a neutralizing antibody. For Activating antibodies, agonist protocol can be used and for Anti-Ligand antibody, a pre- incubation of ligand with the anti-ligand antibody is recommended for 15-30 minutes before the agonist incubation of 3 hours. Figure 1. PathHunter Receptor Tyrosine Kinase Assay Principle. 4 13 QUICK-START PROCEDURE : ANTIBODY/INHIBITOR DOSE RESPONSE STORAGE CONDITIONS PATHHUNTER EXPRESS COMPONENTS REQUIRE MULTIPLE STORAGE TEMPERATURES. OPEN BOXES IMMEDIATELY AND STORE CONTENTS AS INSTRUCTED. Plate 100 µL PathHunter Cells/Well BOX 1: PATHHUNTER EXPRESS CELLS: Store at -80°C* NOTE: PathHunter eXpress cells arrive frozen on dry ice. Cells are delivered in 1 vial containing 1 x 106 Incubate cells in 100 µL of freezing medium. The vial contains sufficient cell numbers to generate (1) 96- 24 or 48 hours well microplate prepared at the seeding density described. @ 37°C *For short term storage (2 weeks or less), store vials at -80°C immediately upon arrival. For storage longer than 2 weeks, place vials in the vapor phase of liquid nitrogen (N2). Do not touch the bottom of the tubes at any time to avoid inadvertent thawing of the cells. If cells are not frozen upon arrival, do not proceed. Contact technical support.
Load more

Recommended publications
  • The Proximal Signaling Network of the BCR-ABL1 Oncogene Shows a Modular Organization
    Oncogene (2010) 29, 5895–5910 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization B Titz, T Low, E Komisopoulou, SS Chen, L Rubbi and TG Graeber Crump Institute for Molecular Imaging, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA BCR-ABL1 is a fusion tyrosine kinase, which causes signaling effects of BCR-ABL1 toward leukemic multiple types of leukemia. We used an integrated transformation. proteomic approach that includes label-free quantitative Oncogene (2010) 29, 5895–5910; doi:10.1038/onc.2010.331; protein complex and phosphorylation profiling by mass published online 9 August 2010 spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal Keywords: adaptor protein; BCR-ABL1; phospho- BCR-ABL1 signaling network shows a modular and complex; quantitative mass spectrometry; signaling layered organization with an inner core of three leukemia network; systems biology transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/ Dok2 complex). We introduced an ‘interaction direction- ality’ analysis, which annotates static protein networks Introduction with information on the directionality of phosphorylation- dependent interactions. In this analysis, the observed BCR-ABL1 is a constitutively active oncogenic fusion network structure was consistent with a step-wise kinase that arises through a chromosomal translocation phosphorylation-dependent assembly of the Grb2/Gab2/ and causes multiple types of leukemia. It is found in Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 many cases (B25%) of adult acute lymphoblastic core.
    [Show full text]
  • Host-Pathogen Systems Biology: Logical Modelling of Hepatocyte
    BMC Systems Biology BioMed Central Research article Open Access Host-pathogen systems biology: logical modelling of hepatocyte growth factor and Helicobacter pylori induced c-Met signal transduction Raimo Franke†1, Melanie Müller†1, Nicole Wundrack1, Ernst-Dieter Gilles2, Steffen Klamt2, Thilo Kähne1 and Michael Naumann*1 Address: 1Institute of Experimental Internal Medicine, Otto von Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany and 2Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany Email: Raimo Franke - [email protected]; Melanie Müller - [email protected]; Nicole Wundrack - [email protected]; Ernst-Dieter Gilles - [email protected]; Steffen Klamt - Klamt@mpi- magdeburg.mpg.de; Thilo Kähne - [email protected]; Michael Naumann* - [email protected] * Corresponding author †Equal contributors Published: 14 January 2008 Received: 3 October 2007 Accepted: 14 January 2008 BMC Systems Biology 2008, 2:4 doi:10.1186/1752-0509-2-4 This article is available from: http://www.biomedcentral.com/1752-0509/2/4 © 2008 Franke et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The hepatocyte growth factor (HGF) stimulates mitogenesis, motogenesis, and morphogenesis in a wide range of tissues, including epithelial cells, on binding to the receptor tyrosine kinase c-Met. Abnormal c-Met signalling contributes to tumour genesis, in particular to the development of invasive and metastatic phenotypes.
    [Show full text]
  • RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
    G C A T T A C G G C A T genes Review RET Gene Fusions in Malignancies of the Thyroid and Other Tissues Massimo Santoro 1,*, Marialuisa Moccia 1, Giorgia Federico 1 and Francesca Carlomagno 1,2 1 Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, 80131 Naples, Italy; [email protected] (M.M.); [email protected] (G.F.); [email protected] (F.C.) 2 Institute of Endocrinology and Experimental Oncology of the CNR, 80131 Naples, Italy * Correspondence: [email protected] Received: 10 March 2020; Accepted: 12 April 2020; Published: 15 April 2020 Abstract: Following the identification of the BCR-ABL1 (Breakpoint Cluster Region-ABelson murine Leukemia) fusion in chronic myelogenous leukemia, gene fusions generating chimeric oncoproteins have been recognized as common genomic structural variations in human malignancies. This is, in particular, a frequent mechanism in the oncogenic conversion of protein kinases. Gene fusion was the first mechanism identified for the oncogenic activation of the receptor tyrosine kinase RET (REarranged during Transfection), initially discovered in papillary thyroid carcinoma (PTC). More recently, the advent of highly sensitive massive parallel (next generation sequencing, NGS) sequencing of tumor DNA or cell-free (cfDNA) circulating tumor DNA, allowed for the detection of RET fusions in many other solid and hematopoietic malignancies. This review summarizes the role of RET fusions in the pathogenesis of human cancer. Keywords: kinase; tyrosine kinase inhibitor; targeted therapy; thyroid cancer 1. The RET Receptor RET (REarranged during Transfection) was initially isolated as a rearranged oncoprotein upon the transfection of a human lymphoma DNA [1].
    [Show full text]
  • Imatinib Dependent Tyrosine Phosphorylation Profiling of Bcr-Abl
    Provided by the author(s) and University College Dublin Library in accordance with publisher policies. Please cite the published version when available. Title Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells Authors(s) Preisinger, C.; Schwarz, J. P.; Bleijerveld, O. B.; et al. Publication date 2012-08-27 Publication information Leukemia, 27 (3): 743-746 Publisher Nature Publishing Group Item record/more information http://hdl.handle.net/10197/5078 Publisher's version (DOI) 10.1038/leu.2012.243 Downloaded 2021-09-25T14:43:28Z The UCD community has made this article openly available. Please share how this access benefits you. Your story matters! (@ucd_oa) © Some rights reserved. For more information, please see the item record link above. 1 Imatinib dependent tyrosine phosphorylation profiling of Bcr-Abl 2 positive chronic myeloid leukemia cells 3 Bcr-Abl is the major cause and pathogenetic principle of chronic myeloid leukemia (CML). 4 Bcr-Abl results from a chromosomal translocation that fuses the bcr and the abl genes, 5 thereby generating a constitutively active tyrosine kinase, which stimulates several signaling 6 networks required for proliferation and survival. Bcr-Abl’s oncogenic properties comprise 7 both functions as a kinase and as a scaffold protein 1. A number of Bcr-Abl interaction 8 partners and downstream effectors have been described, improving our understanding of the 9 signaling networks deranged in CML. Brehme et al. recently defined the “core-interactome of 10 Bcr-Abl”, identifying seven major interaction partners of Bcr-Abl (GRB2, Shc1, Crk, c-Cbl, 11 p85, Sts-1, and SHIP-2) 2.
    [Show full text]
  • Detection of a Rare BCR–ABL Tyrosine Kinase Fusion Protein in H929 Multiple Myeloma Cells Using Immunoprecipitation (IP)-Tandem Mass Spectrometry (MS/MS)
    Detection of a rare BCR–ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS) Susanne B. Breitkopfa,b, Min Yuana, German A. Pihanc, and John M. Asaraa,b,1 aDivision of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115; bDepartment of Medicine, Harvard Medical School, Boston, MA 02115; and cDepartment of Hematopathology, Beth Israel Deaconess Medical Center, Boston, MA 02115 Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved August 23, 2012 (received for review July 26, 2012) Hypothesis directed proteomics offers higher throughput over Here, we focused on a hypothesis-directed approach to identify global analyses. We show that immunoprecipitation (IP)–tandem the active signaling pathways that drive cancers. To this end, we mass spectrometry (LC-MS/MS) in H929 multiple myeloma (MM) immunoprecipitated proteins that have clinical significance in cell cancer cells led to the discovery of a rare and unexpected BCR– proliferation such as the central nodes in the AKT and ERK sig- ABL fusion, informing a therapeutic intervention using imatinib naling pathways. The p85 regulatory subunit of phosphoinositide- (Gleevec). BCR–ABL is the driving mutation in chronic myeloid leu- 3-kinase (PI3K) binds pYXXM motif-containing proteins to the kemia (CML) and is uncommon to other cancers. Three different IP– SRC homology 2 (SH2) domains of p85, thus recruiting the p110 MS experiments central to cell signaling pathways were sufficient to catalytic subunit to the plasma membrane for activation (5, 17). Activated p110 phosphorylates its lipid substrate phosphatidyli- discover a BCR–ABL fusion in H929 cells: phosphotyrosine (pY) pep- nositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-tri- tide IP, p85 regulatory subunit of phosphoinositide-3-kinase (PI3K) phosphate (PIP3) and binds to the pleckstrin homology (PH) IP, and the GRB2 adaptor IP.
    [Show full text]
  • Ephrin-B1 Forward Signaling Regulates Craniofacial Morphogenesis by Controlling Cell Proliferation Across Eph–Ephrin Boundaries
    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph–ephrin boundaries Jeffrey O. Bush1 and Philippe Soriano1,2 Program in Developmental Biology and Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA; and Department of Developmental and Regenerative Biology, Mt. Sinai School of Medicine, New York, New York 10029, USA Mutations in the X-linked human EPHRIN-B1 gene result in cleft palate and other craniofacial anomalies as part of craniofrontonasal syndrome (CFNS), but the molecular and developmental mechanisms by which ephrin-B1 controls the underlying developmental processes are not clear. Here we demonstrate that ephrin-B1 plays an intrinsic role in palatal shelf outgrowth in the mouse by regulating cell proliferation in the anterior palatal shelf mesenchyme. In ephrin-B1 heterozygous mutants, X inactivation generates ephrin-B1-expressing and -nonex- pressing cells that sort out, resulting in mosaic ephrin-B1 expression. We now show that this process leads to mosaic disruption of cell proliferation and post-transcriptional up-regulation of EphB receptor expression through relief of endocytosis and degradation. The alteration in proliferation rates resulting from ectopic Eph–ephrin expression boundaries correlates with the more severe dysmorphogenesis of ephrin-B1+/À heterozygotes that is a hallmark of CFNS. Finally, by integrating phosphoproteomic and transcriptomic approaches, we show that ephrin-B1 controls proliferation in the palate by regulating the extracellular signal-regulated kinase/mitogen- activated protein kinase (ERK/MAPK) signal transduction pathway. [Keywords: Ephrin; cell proliferation; ERK/MAPK; endocytosis; boundaries; craniofrontonasal syndrome; palate] Supplemental material is available at http://www.genesdev.org.
    [Show full text]
  • Has Programmed Cell Death Ligand-1 MET an Accomplice in Non-Small Cell Lung Cancer?—A Narrative Review
    2682 Review Article Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review Wolfram C. M. Dempke1, Klaus Fenchel2 1Department of Haematology and Oncology, University of Munich, Munich, Germany; 2Medical Oncology Clinic, Saalfeld, Germany Contributions: (I) Conception and design: Both authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: Both authors; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Wolfram C. M. Dempke, MD, PhD, MBA. Department of Haematology and Oncology, Medical Clinic III (Campus Grosshadern), Marchinoninistr. 15, D-81377 Munich, Germany. Email: [email protected]. Abstract: Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non- small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Several experimental studies have provided compelling evidence that c-MET is involved in the regulation of the immune response by up- regulating inhibitory molecules (e.g., PD-L1) and down-regulating of immune stimulators (e.g., CD137, CD252, CD70, etc.). In addition, c-MET was found to be implicated in the regulation of the inflamed tumour microenvironment (TME) and thereby contributing to an increased immune escape of tumour cells from T cell killing. Moreover, it is a major resistance mechanism following treatment of epidermal growth factor receptor mutations (EGFRmut) with tyrosine kinase receptor inhibitors (TKIs). In line with these findings c-MET alterations have also been shown to be associated with a worse clinical outcome and a poorer prognosis in NSCLC patients.
    [Show full text]
  • The Function and Therapeutic Targeting of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Brandon Golding, Anita Luu, Robert Jones and Alicia M
    Golding et al. Molecular Cancer (2018) 17:52 https://doi.org/10.1186/s12943-018-0810-4 REVIEW Open Access The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) Brandon Golding, Anita Luu, Robert Jones and Alicia M. Viloria-Petit* Abstract Lung cancer is the leading cause of death by cancer in North America. A decade ago, genomic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase were identified in a subset of non-small cell lung carcinoma (NSCLC) patients. Soon after, crizotinib, a small molecule ATP-competitive ALK inhibitor was proven to be more effective than chemotherapy in ALK-positive NSCLC patients. Crizotinib and two other ATP-competitive ALK inhibitors, ceritinib and alectinib, are approved for use as a first-line therapy in these patients, where ALK rearrangement is currently diagnosed by immunohistochemistry and in situ hybridization. The clinical success of these three ALK inhibitors has led to the development of next-generation ALK inhibitors with even greater potency and selectivity. However, patients inevitably develop resistance to ALK inhibitors leading to tumor relapse that commonly manifests in the form of brain metastasis. Several new approaches aim to overcome the various mechanisms of resistance that develop in ALK-positive NSCLC including the knowledge-based alternate and successive use of different ALK inhibitors, as well as combined therapies targeting ALK plus alternative signaling pathways. Key issues to resolve for the optimal implementation of established and emerging treatment modalities for ALK-rearranged NSCLC therapy include the high cost of the targeted inhibitors and the potential of exacerbated toxicities with combination therapies.
    [Show full text]
  • Figure S1. GO Analysis of Genes in Glioblastoma Cases That Showed Positive and Negative Correlations with TCIRG1 in the GSE16011 Cohort
    Figure S1. GO analysis of genes in glioblastoma cases that showed positive and negative correlations with TCIRG1 in the GSE16011 cohort. (A‑C) GO‑BP, GO‑CC and GO‑MF terms of genes that showed positive correlations with TCIRG1, respec‑ tively. (D‑F) GO‑BP, GO‑CC and GO‑MF terms of genes that showed negative correlations with TCIRG1. Red nodes represent gene counts, and black bars represent negative 1og10 P‑values. TCIRG1, T cell immune regulator 1; GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function. Table SI. Genes correlated with T cell immune regulator 1. Gene Name Pearson's r ARPC1B Actin‑related protein 2/3 complex subunit 1B 0.756 IL4R Interleukin 4 receptor 0.695 PLAUR Plasminogen activator, urokinase receptor 0.693 IFI30 IFI30, lysosomal thiol reductase 0.675 TNFAIP3 TNF α‑induced protein 3 0.675 RBM47 RNA binding motif protein 47 0.666 TYMP Thymidine phosphorylase 0.665 CEBPB CCAAT/enhancer binding protein β 0.663 MVP Major vault protein 0.660 BCL3 B‑cell CLL/lymphoma 3 0.657 LILRB3 Leukocyte immunoglobulin‑like receptor B3 0.656 ELF4 E74 like ETS transcription factor 4 0.652 ITGA5 Integrin subunit α 5 0.651 SLAMF8 SLAM family member 8 0.647 PTPN6 Protein tyrosine phosphatase, non‑receptor type 6 0.641 RAB27A RAB27A, member RAS oncogene family 0.64 S100A11 S100 calcium binding protein A11 0.639 CAST Calpastatin 0.638 EHBP1L1 EH domain‑binding protein 1‑like 1 0.638 LILRB2 Leukocyte immunoglobulin‑like receptor B2 0.629 ALDH3B1 Aldehyde dehydrogenase 3 family member B1 0.626 GNA15 G protein
    [Show full text]
  • THE ROLE of NPM-ALK SIGNALING in TUMOR CELL METABOLISM By
    THE ROLE OF NPM-ALK SIGNALING IN TUMOR CELL METABOLISM by Scott Robert Paul McDonnell A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2013 Doctoral Committee: Professor Megan S. Lim, Chair Professor Kathleen Cho Research Associate Professor Nicholas Donato Associate Professor Peter C. Lucas Assistant Professor Ivan Maillard Assistant Professor Zaneta Nikolovska-Coleska © Scott Robert Paul McDonnell 2013 to children with cancer ii ACKNOWLEDGEMENTS Graduate school has been an amazing time in my life, and many people throughout my tenure at Michigan have played vital roles in my thesis work. Whether through mentorship, collaborative research or emotional support, everyone in my life has contributed to this body of work presented here. My success is yours and I can’t thank you enough. My mentors Dr. Megan Lim and Dr. Kojo Elenitoba-Johnson have been immensely critical to this work. I thank you both for your guidance, advice and support during my graduate career. I have been very lucky to be mentored by two incredibly intelligent individuals who constantly put my needs as a graduate student above their own, as this is a quality not easy to come by. I would also like to acknowledge my thesis committee members (Dr. Lucas, Dr. Cho, Dr. Donato, Dr. Maillard and Dr. Nikolovska-Coleska) for their support and guidance throughout my graduate career. I also truly appreciate the support from Dr. Nick Lukacs and the Pathology graduate program, including Laura Hessler and Laura Labut. I would also like to thank the members (past and present) of the Lim and Elenitoba-Johnson labs.
    [Show full text]
  • Downloaded from the Gene Expression Omnibus (GSE25219) Were Used for the Assessment of Prenatal Gene Expression
    UCLA UCLA Electronic Theses and Dissertations Title Investigation of sex-differential genetic risk factors for autism spectrum disorders Permalink https://escholarship.org/uc/item/4cf1h61b Author Werling, Donna Marie Publication Date 2014 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA Los Angeles Investigation of sex-differential genetic risk factors for autism spectrum disorders A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Neuroscience by Donna Marie Werling 2014 © Copyright by Donna Marie Werling 2014 ABSTRACT OF THE DISSERTATION Investigation of sex-differential genetic risk factors for autism spectrum disorders by Donna Marie Werling Doctor of Philosophy in Neuroscience University of California, Los Angeles, 2014 Professor Daniel H. Geschwind, Chair Autism spectrum disorders (ASDs) are pervasive neurodevelopmental disorders that affect more males than females, and the mechanisms responsible for increasing males’ risk or protecting females are not understood. This sex biased prevalence is consistent across time and populations, suggesting that an understanding of the processes driving sex-differential risk would likely be informative of fundamental pathophysiology in ASD. One known component of ASD risk is genetic variation. Thus, here I apply several approaches that leverage current knowledge of ASD genetics to investigate the role and mechanisms of sex-differential biology in ASD risk. First, I evaluate a cohort of families with more than one autistic child for evidence of sex- differential, familial risk variation. Second, I use genetic linkage analysis to identify sex- differential risk loci in families from the same multiplex cohort.
    [Show full text]
  • Review Article Thyroid Cancer: Current Molecular Perspectives
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Journal of Oncology Volume 2010, Article ID 351679, 17 pages doi:10.1155/2010/351679 Review Article Thyroid Cancer: Current Molecular Perspectives Francesca Giusti, Alberto Falchetti, Francesco Franceschelli, Francesca Marini, Annalisa Tanini, and Maria Luisa Brandi Regional Centre for Hereditary Endocrine Tumors, Unit of Metabolic Bone Diseases, Department of Internal Medicine, University of Florence, Viale Morgagni 85, 50135 Florence, Italy Correspondence should be addressed to Maria Luisa Brandi, [email protected]fi.it Received 30 December 2009; Accepted 21 January 2010 Academic Editor: Aysegula A. Sahin Copyright © 2010 Francesca Giusti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The thyroid cancer is a rare oncological entity, representing no more than 1% of all human malignant neoplasms. Recently, it has been demonstrated a sharp increase in incidence of differentiated thyroid carcinoma, equally occurring in both sexes. So far, multiple genetic alterations have been identified in differentiated thyroid carcinoma, leading to investigate the clinical utility of genetic studies. In particular, molecular genetic approaches searching for gene mutations in the material collected by fine needle ago-biopsy may have a particular utility in small nodules and in those specimens with an indeterminate cytology. The expansion of knowledge about genetic mutations occurring in different thyroid tumors has characterized recent years, allowing the identification of a correlation between specific mutations and phenotypic characteristics of thyroid cancers, essential for their prognosis.
    [Show full text]